| Raj Manickam, MD | |
|
1350 Sweet Pea Path, Crownsville, MD 21032-2020 | |
| (410) 987-7375 | |
| Not Available |
| Full Name | Raj Manickam |
|---|---|
| Gender | Male |
| Speciality | Pediatric Medicine |
| Experience | 54 Years |
| Location | 1350 Sweet Pea Path, Crownsville, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649200965 | NPI | - | NPPES |
| 960281000 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | D0018398 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Urgent Care Medicine, Llc | 2163698101 | 4 |
News Archive
Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first cohort of three patients, the Safety Monitoring Board has approved moving to the next cohort and transplantation of the fourth patient.
The neurodegenerative disease spinocerebellar ataxia type 5 (SCA5) damages nerve cells in two ways. University of Minnesota researchers now report that the defective protein responsible for the disease cuts the number of synaptic terminals and snarls traffic inside neurons.
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.
By carefully matching the estimated function of kidneys from deceased donors with the needs of potential recipients, surgeons can successfully transplant kidneys that would otherwise be discarded, according to a report from Wake Forest University Baptist Medical Center. The center was able to double its transplant volume within a year.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.
› Verified 2 days ago
| Entity Name | Statcare Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780156455 PECOS PAC ID: 6709893803 Enrollment ID: O20060315000179 |
News Archive
Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first cohort of three patients, the Safety Monitoring Board has approved moving to the next cohort and transplantation of the fourth patient.
The neurodegenerative disease spinocerebellar ataxia type 5 (SCA5) damages nerve cells in two ways. University of Minnesota researchers now report that the defective protein responsible for the disease cuts the number of synaptic terminals and snarls traffic inside neurons.
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.
By carefully matching the estimated function of kidneys from deceased donors with the needs of potential recipients, surgeons can successfully transplant kidneys that would otherwise be discarded, according to a report from Wake Forest University Baptist Medical Center. The center was able to double its transplant volume within a year.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.
› Verified 2 days ago
| Entity Name | Health Provider Management, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629361274 PECOS PAC ID: 6800064742 Enrollment ID: O20110721000108 |
News Archive
Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first cohort of three patients, the Safety Monitoring Board has approved moving to the next cohort and transplantation of the fourth patient.
The neurodegenerative disease spinocerebellar ataxia type 5 (SCA5) damages nerve cells in two ways. University of Minnesota researchers now report that the defective protein responsible for the disease cuts the number of synaptic terminals and snarls traffic inside neurons.
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.
By carefully matching the estimated function of kidneys from deceased donors with the needs of potential recipients, surgeons can successfully transplant kidneys that would otherwise be discarded, according to a report from Wake Forest University Baptist Medical Center. The center was able to double its transplant volume within a year.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.
› Verified 2 days ago
| Entity Name | Urgent Care Medicine, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174804918 PECOS PAC ID: 2163698101 Enrollment ID: O20111222000219 |
News Archive
Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first cohort of three patients, the Safety Monitoring Board has approved moving to the next cohort and transplantation of the fourth patient.
The neurodegenerative disease spinocerebellar ataxia type 5 (SCA5) damages nerve cells in two ways. University of Minnesota researchers now report that the defective protein responsible for the disease cuts the number of synaptic terminals and snarls traffic inside neurons.
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.
By carefully matching the estimated function of kidneys from deceased donors with the needs of potential recipients, surgeons can successfully transplant kidneys that would otherwise be discarded, according to a report from Wake Forest University Baptist Medical Center. The center was able to double its transplant volume within a year.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.
› Verified 2 days ago
| Entity Name | Statcare Group Iii, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902261308 PECOS PAC ID: 7214221472 Enrollment ID: O20160810002076 |
News Archive
Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first cohort of three patients, the Safety Monitoring Board has approved moving to the next cohort and transplantation of the fourth patient.
The neurodegenerative disease spinocerebellar ataxia type 5 (SCA5) damages nerve cells in two ways. University of Minnesota researchers now report that the defective protein responsible for the disease cuts the number of synaptic terminals and snarls traffic inside neurons.
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.
By carefully matching the estimated function of kidneys from deceased donors with the needs of potential recipients, surgeons can successfully transplant kidneys that would otherwise be discarded, according to a report from Wake Forest University Baptist Medical Center. The center was able to double its transplant volume within a year.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Raj Manickam, MD 1350 Sweet Pea Path, Crownsville, MD 21032-2020 Ph: (410) 987-7375 | Raj Manickam, MD 1350 Sweet Pea Path, Crownsville, MD 21032-2020 Ph: (410) 987-7375 |
News Archive
Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first cohort of three patients, the Safety Monitoring Board has approved moving to the next cohort and transplantation of the fourth patient.
The neurodegenerative disease spinocerebellar ataxia type 5 (SCA5) damages nerve cells in two ways. University of Minnesota researchers now report that the defective protein responsible for the disease cuts the number of synaptic terminals and snarls traffic inside neurons.
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.
By carefully matching the estimated function of kidneys from deceased donors with the needs of potential recipients, surgeons can successfully transplant kidneys that would otherwise be discarded, according to a report from Wake Forest University Baptist Medical Center. The center was able to double its transplant volume within a year.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.
› Verified 2 days ago